Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1a/1b Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of BBO-11818 in Subjects With Advanced KRAS Mutant Cancers

Next Previous
Search
Trial Profile

A Phase 1a/1b Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of BBO-11818 in Subjects With Advanced KRAS Mutant Cancers

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 06 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs BBO 11818 (Primary) ; Carboplatin (Primary) ; Cetuximab (Primary) ; Cisplatin (Primary) ; Pembrolizumab (Primary) ; Pemetrexed (Primary)
  • Indications Adenocarcinoma; Colorectal cancer; Non-small cell lung cancer; Pancreatic cancer; Solid tumours
  • Focus Adverse reactions; First in man
  • Acronyms KONQUER-101
  • Sponsors BridgeBio Oncology Therapeutics

Most Recent Events

  • 01 Apr 2025 Status changed from planning to recruiting, according to a BridgeBio Oncology Therapeutics media release.
  • 01 Apr 2025 According to a BridgeBio Oncology Therapeutics media release, company announced that the first patient has been dosed with BBO-11818 in the Phase 1 KONQUER-101 trial for advanced solid tumors.
  • 04 Mar 2025 New trial record

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top